Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis

Nephron

Volumn 91, Issue 4, 2002, Pages 654-658

  Kusano, Eiji ^a   Inoue, M ^a   Akai, Y ^a   Furuya, H ^a   Ando, Y ^a   Tabei, K ^a   Asano, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Erythropoietin; Hemodialysis; Hypertension; Nitric oxide; Ticlopidine hydrochloride

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ENDOTHELIN; ERYTHROPOIETIN; NITRIC OXIDE; TICLOPIDINE; VASOACTIVE AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; BLOOD PRESSURE; ERYTHROPOIETIN; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGE; PLATELET AGGREGATION INHIBITORS; RENAL DIALYSIS; SUPPORT, NON-U.S. GOV'T; TICLOPIDINE; HUMANS; MIDDLE AGED;

EID: 0035995361     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065027     Document Type: Article

References (26)

1. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial
2. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy
3. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients
4. Peripheral hemodynamics, blood viscosity, and the reninangiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin
5. Plasma immunoreactive endothelin levels are increased in hemodialysis patients with hypertension following erythropoietin therapy
6. Increased activity of the autonomic nervous system and increased sensitivity to angiotensin II infusion after recombinant human erythropoietin
7. Vascular change in hemodialysis patients in response to recombinant human erythropoietin
8. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients
9. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin
10. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients
11. Hemodynamic changes induced by the correction of anaemia by erythropoietin: Role of antiplatelet therapy
12. Dipyridamole enhances interleukin-1β-stimulated nitric oxide production by cultured rat vascular smooth muscle cells
13. Ticlopidine enhances interleukin-1β-stimulated nitric oxide production by cultured rat vascular smooth muscle cells
14. 15N] nitrate in biological fluids
15. Anti-platelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients
16. Human recombinant erythropoietin inhibits interleukin-1β-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth muscle cells
17. The effect of erythropoietin on interleukin-1β-mediated increase in nitric oxide synthesis in vascular smooth muscle cells
18. Hemodialysis and nitric oxide
19. Ticlopidine increases nitric oxide generation in heart-transplant recipients: A possible novel property of ticlopidine
20. Endothelial dysfunction early after heart transplantation. Assessment with intravascular ultrasound and doppler
21. Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension
22. Cytokines and cardiomyocyte death
23. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet-free calcium mobilization in uraemic children: A possible link?
24. Nitric oxide induces upregulation of fas and apoptosis in vascular smooth muscle
25. Vasoactive substance regulates vascular smooth muscle cell apoptosis-countervailing influences of nitric oxide and angiotensin II
26. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol-3-kinase-dependent pathway